CANCER AND INFECTION SCREENING IN POTENTIAL LIVING DONORS

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

Abstract Title *

CANCER AND INFECTION SCREENING IN POTENTIAL LIVING DONORS

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Bassam Saeed bmsaeed2000@yahoo.com Farah association for Child with Kidney Disease Pediatric Nephrology Damascus Syrian Arab Republic *

Co-author 2

Co-author 3

Co-author 4

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Living donor transplant is a safe practice but is not completely risk free. Although both infection and malignancy transmissions have occurred through living organ donation, in the global view, the number of these events is negligible in contrast to the successful lifesaving transplants performed each year; however, an event can be devastating for the recipient, donor, and treatment team if it occurs

Methods

Each living donor is unique, and the donor evaluation is multifactorial, taking into the account the medical, social, and family history of individual donors, needs of the recipient, and determination of the anatomic and functional suitability of the donor organ

Results

These considerations can be further complicated by geographical and temporal components. Although the balancing of all practical considerations can be complex, a thorough medical assessment for infection and malignancy of a potential living donor is central in protecting the donor and the intended transplant recipient

Conclusion

Good medical practice requires consistent donor evaluation and reasonable follow up

Kewords